Adjuvant Radiotherapy After Radical Cystectomy for Muscle-Invasive Bladder Cancer - Beyond the Abstract

Some patients with high-risk disease after cystectomy may benefit from adjuvant strategies, although systemic treatments including chemotherapy and immunotherapy have controversial results. Several randomized trials seem to suggest a benefit of radiotherapy, in particular when combined with chemotherapy, in terms of reducing locoregional relapse, with a good safety profile. However, there are many biases.

The GETUG-AFU 30 (Bladder-ART) trial is a randomized multicentre study in patients with high-risk muscle-invasive bladder cancer to investigate adjuvant radiotherapy after radical cystectomy and pelvic lymph node dissection. The objective of the study is to provide evidence that adjuvant radiotherapy improves locoregional control with potential benefits in survival. The study will also assess the quality of life of patients and the tolerance of the treatment. It may finally provide an answer to the place of radiotherapy among the adjuvant strategies that can be envisaged in these patients at high risk of recurrence after cystectomy.

Written by: Géraldine Pignot, MD, PhD, Urologist, L'institut Paoli-Calmettes, Marseille, France

Read the Abstract